MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-14-2025
OptiNose Cost of Revenue 2011-2026 | OPTN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue OptiNose
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.63 M | 9.26 M | 9.15 M | 7.52 M | 5.29 M | 1.59 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.26 M | 1.59 M | 6.91 M |
Quarterly Cost of Revenue OptiNose
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.75 M | - | 2.06 M | 1.98 M | 1.23 M | - | 2.22 M | 2.57 M | 1.71 M | - | 2.12 M | 2.14 M | 2.01 M | - | 2.41 M | 2.42 M | 1.74 M | - | - | - | - | - | 1.39 M | 1.09 M | 738 K | - | 319 K | 351 K | 200 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.57 M | 200 K | 1.6 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.06 | -0.93 % | $ 114 M |  Canada |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 0.55 | -3.51 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 4.58 | -5.37 % | $ 64.4 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 38.6 | -27.96 % | $ 1.42 B | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.92 | -0.78 % | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
27 M | $ 11.9 | 1.06 % | $ 845 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Evolus
EOLS
|
100 M | $ 4.13 | -3.73 % | $ 266 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.87 | -4.33 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.37 | -3.52 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
2.76 B | $ 11.39 | -7.89 % | $ 1.58 B | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.9 | -0.12 % | $ 21 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.53 | 0.66 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.22 | -0.89 % | $ 23.2 M | USA |
 |
Veru
VERU
|
11 M | $ 2.52 | -3.82 % | $ 340 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 14.89 | -5.16 % | $ 17.9 B | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.77 | -4.37 % | $ 3.32 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 22.1 | 3.85 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.75 | 0.33 % | $ 35.9 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.75 | -3.17 % | $ 3.41 M | USA |
 |
Tilray
TLRY
|
480 M | $ 7.36 | -3.16 % | $ 4.55 B | Canada |